MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines

Nucleic Acids Res. 2009 Nov;37(20):6681-90. doi: 10.1093/nar/gkp723. Epub 2009 Sep 10.

Abstract

The aim of the present study was to analyse the molecular mechanisms involved in the Interleukin-6 (IL-6) silencing in pancreatic adenocarcinoma cell lines. Our results demonstrate that TNF-alpha, a major IL-6 inducer, is able to induce IL-6 only in three out of six cell lines examined. 5-aza-2'-deoxycytidine (DAC), but not trichostatin A (TSA), activates the expression of IL-6 in all cell lines, indicating that DNA methylation, but not histone deacetylation, plays an essential role in IL-6 silencing. Indeed, the IL-6 upstream region shows a methylation status that correlates with IL-6 expression and binds MeCP2 and H3meK9 only in the non-expressing cell lines. Our results suggest that critical methylations located from positions -666 to -426 relative to the transcription start site of IL-6 may act as binding sites for MeCP2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics*
  • Azacitidine / analogs & derivatives*
  • Azacitidine / pharmacology
  • CCAAT-Enhancer-Binding Protein-alpha / metabolism
  • Cell Line, Tumor
  • Chromatin Immunoprecipitation
  • DNA / metabolism
  • DNA Methylation
  • Decitabine
  • Gene Silencing*
  • Humans
  • Hydroxamic Acids / pharmacology
  • Interleukin-6 / antagonists & inhibitors*
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • Methyl-CpG-Binding Protein 2 / metabolism*
  • NF-kappa B / metabolism
  • Pancreatic Neoplasms / genetics*

Substances

  • CCAAT-Enhancer-Binding Protein-alpha
  • Hydroxamic Acids
  • Interleukin-6
  • MECP2 protein, human
  • Methyl-CpG-Binding Protein 2
  • NF-kappa B
  • trichostatin A
  • Decitabine
  • DNA
  • Azacitidine